Volume 4.50 | Dec 20

Mammary Cell News 4.50 December 20, 2012
Mammary Cell News
     In this issue: Publications | Reviews Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Mammary Cell News on Twitter
TGF-β Upregulates miR-181a Expression to Promote Breast Cancer Metastasis
Scientists established microRNA (miR)-181a as a TGF-β-regulated “metastamir” that enhanced the metastatic potential of breast cancers by promoting epithelial-mesenchymal transition, migratory, and invasive phenotypes. [J Clin Invest] Full Article | Press Release

Don't Lose Sleep Over Mouse Mammary Tissue Dissociation (New Enzymes: Learn More)
PUBLICATIONS (Ranked by impact factor of the journal)


Autocrine Motility Factor Promotes HER2 Cleavage and Signaling in Breast Cancer Cells
Researchers showed that autocrine motility factor binds to HER2 and induces cleavage to the ectodomain-deleted and constitutively active form p95HER2. [Cancer Res] Abstract

Contrasting Hypoxic Effects on Breast Cancer Stem Cell Hierarchy Is Dependent on ERα Status
Scientists studied the effects of hypoxia on cancer stem cel activity, using in vitro mammosphere and holoclone assays as well as in vivo limiting dilution experiments, in 13 patient-derived samples and four cell lines. [Cancer Res] Abstract

Fibroblast Growth Factor Receptor Signaling Is Essential for Normal Mammary Gland Development and Stem Cell Function
Using a conditional deletion strategy, the authors investigated the consequences of fibroblast growth factor receptor-1 (FGFR1) deletion alone and then the simultaneous deletion of both FGFR1 and FGFR2 in the mammary epithelium. [Stem Cells] Abstract

ROCK1 Inhibition Promotes the Self-Renewal of a Novel Mouse Mammary Cancer Stem Cell
Researchers identified epithelial tumor-initiating cells that express lineage markers of both basal and luminal mammary cell lineages and retain the potential, from even single cells, to generate heterogeneous tumors similar to the tumor of origin. [Stem Cells] Abstract

Depletion of Tristetraprolin in Breast Cancer Cells Increases Interleukin-16 Expression and Promotes Tumor Infiltration with Monocytes/Macrophages
As immune cell infiltration into tumors is a critical determinant for tumor progression, the authors aimed to determine the influence of tumor cell tristetraprolin on the interaction between tumor and immune cells, specifically monocytes/macrophages. [Carcinogenesis] Abstract

Estrogen Switches Pure Mucinous Breast Cancer to Invasive Lobular Carcinoma with Mucinous Features
Because of the relative rarity of pure mucinous breast cancer (MBC), little is known about its cell and tumor biology and relationship to invasive disease of other subtypes. Investigators have developed a human breast cancer cell line called BCK4, in which they can control the behavior of MBC. [Breast Cancer Res Treat] Abstract

Differential Expression of Immune-Related Markers in Breast Cancer by Molecular Phenotypes
Scientists aimed to investigate the relationship between expression of immune-related molecules such as STAT1, CD20, IL-8, IFN-γ, tumor genetic phenotype, and the clinical course of invasive breast cancer. [Breast Cancer Res Treat] Abstract


Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide in Node-Positive Breast Cancer: Ten-Year Follow-Up of the Phase III Randomized BCIRG 001 Trial
Researchers compared standard adjuvant anthracycline chemotherapy with anthracycline-taxane combination chemotherapy in women with operable node-positive breast cancer. Here they report the final, ten-year follow-up analysis of disease-free survival, overall survival, and long-term safety. [Lancet Oncol] Abstract

A Phase II Study of UCN-01 in Combination with Irinotecan in Patients with Metastatic Triple Negative Breast Cancer
The high frequency of TP53 mutations in triple negative breast cancer (TNBC) make checkpoint kinase 1 (Chk1) an attractive therapeutic target. UCN-01, a non-selective Chk1 inhibitor, combined with irinotecan demonstrated activity in advanced TNBC in a previous Phase I study. Researchers aimed to further evaluate this treatment in women with TNBC. [Breast Cancer Res Treat] Full Article

FREE ALDEFLUOR™ Protocol Optimization Resource Pack – Get Yours

Emerging Strategies for the Dual Inhibition of HER2-Positive Breast Cancer
The author reviews the recently published trials to help refine and optimize the use of approved HER2-targeted agents (trastuzumab and lapatinib) and highlight future combination strategies for the treatment of HER2-positive breast cancer. [Curr Opin Obstet Cynecol] Abstract
Changes in Progenitor Cell Population in Breast May Be Overlooked Factor in Breast Cancer
The DNA mutations that accumulate over time as women age are not the sole contributor to the higher frequency of breast cancer in women over 50, Mark LaBarge, PhD, a researcher at Lawrence Berkeley National Laboratory reported. [Press release from EurekAlert! discussing research presented at the American Society for Cell Biology Annual Meeting, San Francisco] Press Release

NCC to Expand International Programs Aimed at Fighting Women’s Cancers
The National Cancer Coalition (NCC) is expanding its efforts to fight women’s cancers in the developing world. NCC has pledged to increase its commitment to assist underserved women’s cancer patients at-risk of breast, cervical or ovarian cancers. [PR Newswire Association LLC] Press Release

Alliance for Regenerative Medicine Forms Tissue Engineering and Biomaterials Committee
The Alliance for Regenerative Medicine announced the formation of a Tissue Engineering and Biomaterials Committee (TEBC). The TEBC has been established to assemble the companies, academic institutions, and organizations within the Alliance for Regenerative Medicine that develop and commercialize tissue engineered and biomaterial based technologies. [Alliance for Regenerative Medicine] Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW The International Congress on Oncological Perspectives of Fertility Preservation: Gynecological & Breast Cancer
March 21-23, 2013
Berlin, Germany

our events page to see a complete list of events in the mammary cell community.


Product Quality Scientist (STEMCELL Technologies, Inc.)

Scientist – Endothelial Cell Research (STEMCELL Technologies, Inc.)

Research Technologist – Cell Separation (STEMCELL Technologies, Inc.)

Scientist or Engineer – hPSC Bioengineer (STEMCELL Technologies, Inc.)

Postdoctoral Position – Tumor Stem Cells (Cancer Institute of New Jersey)

Laboratory Heads – Developmental Biology and Stem Cell Biology (RIKEN Center for Developmental Biology)

Assistant Professor – Breast Cancer (Cedars-Sinai Medical Center)

Principal Investigator – Cancer Research (Institut de Recherches Cliniques de Montréal)

Postdoctoral Position – Genetic Biomarkers in Breast Cancer (Rush University Medical Center)

Postdoctoral Position – Functional Characterization of Novel Candidate Oncogenes Implicated in Breast Cancer (The Netherlands Cancer Institute)

PhD Studentship – Integrated Classification of Breast Cancers to Optimize Treatment Protocols (Radboud University Nijmegen Medical Centre)

Recruit Top Talent
: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives | Events | Contact Us